GB2412066A - Method of reducing toxicity of anticancer agents - Google Patents

Method of reducing toxicity of anticancer agents Download PDF

Info

Publication number
GB2412066A
GB2412066A GB0514044A GB0514044A GB2412066A GB 2412066 A GB2412066 A GB 2412066A GB 0514044 A GB0514044 A GB 0514044A GB 0514044 A GB0514044 A GB 0514044A GB 2412066 A GB2412066 A GB 2412066A
Authority
GB
United Kingdom
Prior art keywords
anticancer agents
reducing toxicity
toxicity
reducing
cancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0514044A
Other versions
GB0514044D0 (en
GB2412066B (en
Inventor
Youcef Rustum
Shousong Cao
Farukh Durrani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of GB0514044D0 publication Critical patent/GB0514044D0/en
Publication of GB2412066A publication Critical patent/GB2412066A/en
Application granted granted Critical
Publication of GB2412066B publication Critical patent/GB2412066B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses a method for reducing the toxicity of anti-cancer agents. The method comprises administering to an individual, in need of such a treatment, an anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Description

GB 2412066 A continuation (74) Agent and/or Address for Service: (58)
Field of Search by ISA: Mathys & Squire Other: U.S: 514/35, 274, 283, 449, 492 and 561.
Holborn, LONDON, EC1N 2SQ, ONLINE: REGISTRY, CAPLUS, MEDLINE, United Kingdom EMBASE, DRUGU, BIOTECHNO, CABA, IPA, BIOSIS, TOXCENTER, WPIDS.
GB0514044A 2002-12-10 2003-12-10 Method of reducing toxicity of anticancer agents Expired - Fee Related GB2412066B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/315,721 US6939893B2 (en) 2002-12-10 2002-12-10 Method of reducing toxicity of anticancer agents
PCT/US2003/039269 WO2004052376A1 (en) 2002-12-10 2003-12-10 Method of reducing toxicity of anticancer agents

Publications (3)

Publication Number Publication Date
GB0514044D0 GB0514044D0 (en) 2005-08-17
GB2412066A true GB2412066A (en) 2005-09-21
GB2412066B GB2412066B (en) 2006-08-30

Family

ID=32468782

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0514044A Expired - Fee Related GB2412066B (en) 2002-12-10 2003-12-10 Method of reducing toxicity of anticancer agents

Country Status (6)

Country Link
US (2) US6939893B2 (en)
CN (1) CN100346794C (en)
AU (1) AU2003296451A1 (en)
CA (1) CA2507540A1 (en)
GB (1) GB2412066B (en)
WO (1) WO2004052376A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2417685B (en) * 2003-05-13 2007-12-19 Health Research Inc Method for augmenting the antitumor activity of anti-cancer agents

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534818B1 (en) * 2003-09-15 2009-05-19 Health Research, Inc. Method of reducing alopecia and bladder toxicity of cyclophosphamide
KR101152276B1 (en) * 2004-08-27 2012-06-08 재단법인서울대학교산학협력재단 Composition for preventing or treating inhibition of gap junctional intercellular communication containing se-(methyl)seleocysteine or seleno-l-methionine
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
CN102327620A (en) * 2011-07-29 2012-01-25 暨南大学 Application of nano-selenium in antineoplastic drug carrier
CN105001406B (en) * 2015-06-16 2018-04-17 湖南大学 The new method of selenocysteine in a kind of detection live body

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617189A (en) * 1983-04-14 1986-10-14 Stockel Richard F Use of selenium-containing compounds for negating the toxic effects of platinum compounds used in chemotherapy, and a novel selenium-containing platinum compound and use thereof as an anti-cancer medicine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552440A (en) * 1994-12-05 1996-09-03 The University Of Kentucky Research Foundation Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer
US6197295B1 (en) * 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617189A (en) * 1983-04-14 1986-10-14 Stockel Richard F Use of selenium-containing compounds for negating the toxic effects of platinum compounds used in chemotherapy, and a novel selenium-containing platinum compound and use thereof as an anti-cancer medicine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS Abstract Acc. No.31:306769 of Archiv. Biochem. Biophys., 1999, Vol.368(2), Konorev et al., pp.421-428. *
J. Dermat. Sci., 2001, Vol.5(1), Korac et al., pp.45-52. *
J. Trace Elements in Experimental Med., 1997, Vol.10(3), Chen et al., pp.163-171. *
Pharmazie, 2000, Vol.55(12), Sieja et al., pp.958-959. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2417685B (en) * 2003-05-13 2007-12-19 Health Research Inc Method for augmenting the antitumor activity of anti-cancer agents

Also Published As

Publication number Publication date
US6939893B2 (en) 2005-09-06
WO2004052376A1 (en) 2004-06-24
AU2003296451A1 (en) 2004-06-30
US20040110838A1 (en) 2004-06-10
GB0514044D0 (en) 2005-08-17
CA2507540A1 (en) 2004-06-24
CN100346794C (en) 2007-11-07
CN1720053A (en) 2006-01-11
US20040180099A1 (en) 2004-09-16
GB2412066B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001078701A3 (en) Method and compositions for preventing hormone induced adverse effects
MXPA04012965A (en) Viral inhibitors.
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
MXPA02012817A (en) Liposomal antineoplastic drugs and uses thereof.
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
BG105302A (en) Means for improving cognition
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CY2462B1 (en) Cyclohexyl dihydrobenzofuranes.
MY128061A (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
GB2412066A (en) Method of reducing toxicity of anticancer agents
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
MX9709451A (en) Benzisoxazole and indazole derivatives as antipsychotic agents.
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU3777197A (en) Cyclosporin formulation
GB2417685A (en) Method for augmenting the antitumor activity of anti-cancer agents

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20121210